BMKDF.US BioMark Diagnostics Inc

Healthcare Biotechnology USA Stocks
0.3221 USD
Close of Nov 13, 2026
0.2259 0.5044
Market cap
USD 34.3M
P/E
-
P/B
85.19x
ROE
-255.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is BMKDF.US undervalued?

Graham number

The Graham number of BioMark Diagnostics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

BioMark Diagnostics Inc fundamental analysis

No fundamental analysis for BioMark Diagnostics Inc yet.

BioMark Diagnostics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About BioMark Diagnostics Inc

Biomark Diagnostics Inc. develops early-stage cancer diagnostic technology platform to detect and treat cancer. The company invests in and develops a liquid biopsy metabolic panel assay for the early-stage diagnosis of lung cancer and glioblastoma (GBM) breast cancer. It is also developing liquid biopsy tests for various cancer types, including glioblastoma, gastrointestinal, prostate, head, neck cancers. The company was incorporated in 2014 and is headquartered in Richmond,…

Full company profile